Dataset Information

Magnesium as a Conformational Gatekeeper of KRAS: Structural Dynamics and Therapeutic Implications

ABSTRACT: Magnesium serves as an essential cofactor for small GTPases, yet its structural role in regulating KRAS conformational dynamics and nucleotide exchange remains poorly understood. Here, we combine hydrogen–deuterium exchange mass spectrometry (HDX-MS), native mass spectrometry, and functional assays to elucidate how Mg²⁺ stabilizes the KRAS conformational ensemble and constrains transitions between GDP- and GTP-bound states. Mg²⁺ removal triggers widespread increases in structural dynamics throughout KRAS—spanning the p-loop, α1-helix, switch I, nucleotide-binding region, and distal helices—revealing a global loosening of the protein fold that favors an open, nucleotide exchange-competent state. Mg²⁺ titration experiments demonstrate that individual structural elements exhibit distinct Mg²⁺ dependencies: the p-loop and α1-helix recover native dynamics at micromolar concentrations, whereas switch I requires millimolar levels, underscoring its exceptionally high sensitivity to Mg²⁺ for structural stabilization. KRAS bound to the catalytic domain of exchange factor SOS1 displays an HDX signature closely resembling the Mg²⁺-free state, indicating that SOS1 promotes nucleotide exchange by transiently perturbing Mg²⁺ coordination while simultaneously stabilizing switch I. Consistently, phosphomimetic KRAS S17E variant, which disrupts a critical Mg²⁺-coordinating residue, exhibits pronounced global destabilization—reinforcing the central importance of Mg²⁺ in maintaining structural integrity. Taken together our findings show that Mg²⁺ acts as a master regulator of KRAS structural dynamics and reveal Mg²⁺-sensitive hotspots that might represent promising targets for next-generation KRAS therapeutics.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Thomas Wales

LAB HEAD: Thomas E. Wales

PROVIDER: PXD074470 | Pride | 2026-06-29

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	10_G12DKRAS_EDTA_10m1.raw.zip	Raw
	10_G12DKRAS_EDTA_10m2.raw.zip	Raw
	10_G12DKRAS_EDTA_10s1.raw.zip	Raw
	10_G12DKRAS_EDTA_10s2.raw.zip	Raw
	10_G12DKRAS_EDTA_1h1.raw.zip	Raw

Items per page:

1 - 5 of 209

Publications

Magnesium as a conformational gatekeeper of KRAS: Structural dynamics and therapeutic implications.

Srinivasu Bindu Y BY Damerla Tanvi S TS Stec Alexander A Zhou Zhiwei Z Engen John R JR Westover Kenneth D KD Wales Thomas E TE

Protein science : a publication of the Protein Society 20260701 7

Magnesium serves as an essential cofactor for small GTPases, yet its structural role in regulating KRAS conformational dynamics and nucleotide exchange remains poorly understood. Here, we combine hydrogen-deuterium exchange mass spectrometry (HDX-MS), native mass spectrometry, and functional assays to elucidate how Mg<sup>2+</sup> stabilizes the KRAS conformational ensemble and constrains transitions between GDP- and GTP-bound states. Depletion of Mg<sup>2+</sup> triggers widespread increases in ...[more]

PMID: 42313706

Similar Datasets

Project description:Src family kinases are often overexpressed and constitutively active in cancer cells, where they represent promising targets for therapeutic intervention. In myeloid hematopoietic cells, Hck, Lyn, and Fgr are associated with both chronic and acute forms of myeloid leukemia. All three of these kinases are expressed in acute myeloid leukemia (AML), where high-level expression correlates with poor survival. The pyrrolopyrimidine Src-family kinase inhibitor A-419259 (also known as RK-20449) has been shown to significantly inhibit patient-derived AML bone marrow cell growth in immunocompromised mice. Recent work has identified an N-phenylbenzamide kinase inhibitor, known as TL02-59, which potently inhibited Fgr kinase activity in vitro and reversed orthotopic engraftment of AML cells in the bone marrow and spleen of immunocompromised mice following oral administration. The inhibitory mechanism of this compound with Fgr or other Src-family members has not been reported. Both wild-type Fgr and a tail mutant (i.e., replacement of Tyr527 with Phe) were shown to produce equal numbers of transformed colonies when expressed in rodent fibroblasts, whereas wild-type Hck transforming activity was completely repressed. In both Hck and Fgr, however, the tail tyrosine residue was shown to be phosphorylated, and hydrogen deuterium exchange mass spectrometry (HDX MS) of near-full-length Fgr was consistent with the closed conformation in solution, with the SH3 domain bound to the SH2-kinase linker and the tail bound to SH2. Here we present the first X-ray crystal structures of near-full-length Fgr bound to the ATP site inhibitors A-419259 and TL02-59. Structural changes induced by the inhibitors in the crystalline state were validated in solution using HDX MS, with A-419259 stabilizing the closed conformation and TL02-59 enhancing exposure of the SH3 domain to solvent. These new structures help to explain the constitutive activity of wild-type Fgr in cells as well as its unique sensitivity to TL02-59, which is currently in development for AML and other maladies.